Drug discovery in ophthalmology: Past success, present challenges, and future opportunities

BMC Ophthalmology

Volumn 16, Issue 1, 2016, Pages

  Gower, Nicholas J D ^a   Barry, Robert J ^a,b   Edmunds, Matthew R ^a,b   Titcomb, Lucy C ^c   Denniston, Alastair K ^a,b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Drug discovery; Ophthalmology; Pharmaceutical

Indexed keywords

DRUG;

DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; OPHTHALMOLOGY; TRENDS;

DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; OPHTHALMOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 84954445485     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-016-0188-2     Document Type: Article

References (105)

1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
2. World Preview 2018: Embracing the Patent Cliff. http://info.evaluatepharma.com/WP2018-ELS-LP.html. Accessed Sept 2015.
3. Pharmaceutical Research and Manufactureres of America. Annual Report 2011. http://www.phrma.org/sites/default/files/159/phrma-2011-annual-report.pdf. Accessed Sept 2015.
4. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov. 2005;4(1):78-84.
5. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia. 1999;1(4):293-302.
6. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med. 2010;16(10):1107-11.
7. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400. doi: 10.1038/nrd1381.
8. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-9.
9. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-4.
10. Avastin 25 mg/ml concentrate for solution for infusion. Bevacizumab. Last updated 22 October 2015. http://www.medicines.org.uk/emc/medicine/15748#INDICATIONS. Accessed Sept 2015.
11. Michelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK. 1948;68:137-80.
12. Lopez PF, Sippy BD, Michael Lambert H, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Investig Ophthalmol Vis Sci. 1996;37:855-68.
13. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investig Ophthalmol Vis Sci. 1996;37:1929-34.
14. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457-61.
15. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114(1):66-71.
16. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene. 2003;22(42):6537-48.
17. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.
18. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536-44.
19. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-46.
20. Heier JS, Antoszyk AN, Pavan PR, Leff, Steven R, Rosenfeld PJ, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113(4):633.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer, David S, Kaiser PK, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.
22. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606-17.
23. Lucentis 10 mg/ml solution for injection. Ranibizumab. Last updated 24 September 2015. http://www.medicines.org.uk/emc/medicine/19409. Accessed Sept 2015
24. Forbes analysis 2013. http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/. Accessed Sept 2015.
25. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:203-14.
26. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov. 2004;3:451-6.
27. Khanna I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov Today. 2012;17:1088-102.
28. Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today. 2013;18:211-7.
29. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507-19.
30. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:428-38.
31. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012;11:541-59.
32. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348-60.
33. Patel A, Cholkar K, Agrahari V, Mitra A. Ocular drug delivery systems: An overview. 2013. http://www.wjgnet.com/2220-3192/full/v2/i2/47.htm. Accessed November 10, 2014
34. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106-23.
35. Strungaru MH, Peck J, Compeau EC, Trope GE, Buys YM. Mirror-hat device as a drop delivery aid: a pilot study. Can J Ophthalmol. 2014;49(4):333-8.
36. An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857-61.
37. Sanabria MR, Montero JA, Losada MV, Fernández-Muñoz M, Galindo A, Fernández I, et al. Ocular pain after intravitreal injection. Curr Eye Res. 2013;38(2):278-82.
38. Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol. 2013;13:18.
39. Hornbeak DM, Payal A, Pistilli M, Biswas J, Ganesh SK, Gupta V, et al. Interobserver agreement in clinical grading of vitreous haze using alternative grading scales. Ophthalmology. 2014;121(8):1643-8.
40. Querques G, Rosenfeld PJ, Cavallero E, Borrelli E, Corvi F, Querques L, et al. Treatment of Dry Age-Related Macular Degeneration. Ophthalmic Res. 2014;52(3):107-15.
41. BCC Research market research report. www.bccresearch.com/market-research/pharmaceuticals/ophthalmic-therapeutic-drugs-phm031c.html. Accessed Sept 2015
42. Reuters 2015 report. www.reuters.com/article/2015/02/10/us-health-glaucoma-idUSKBN0LE0DG20150210. Accessed Sept 2015
43. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005 % in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-45.
44. Moreno-Montañés J, Sádaba B, Ruz V, Gómez-Guiu A, Zarranz J, González MV, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure. Mol Ther. 2014;22(1):226-32.
45. Goldberg DF, Williams R. A Phase 2 study evaluating safety and efficacy of the latanoprost punctal plug delivery system (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). Invest Ophthalmol Vis Sci. 2012;53(e - Abstract):5095.
46. Amadi-Obi A, Yu C-R, Liu X, Mahdi, Rashid M, Clarke GL, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711-8.
47. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa LSH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777-87.
48. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939-48.
49. Curnow SJ, Scheel-Toellner D, Jenkinson W, Raza K, Durrani OM, Faint JM, et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol. 2004;173(8):5290-7.
50. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315-25.
51. Mesquida M, Leszczynska A, Llorenç V, Adán A. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol. 2014;176(3):301-9.
52. Venkiteshwaran A. Tocilizumab. MAbs. 2009;1(5):432-8.
53. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294-5.
54. Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298-302.
55. Oshitari T, Kajita F, Tobe A, Itami M, Yotsukura J, Baba T, et al. Refractory uveitis in patient with castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med. 2012;2012:968180.
56. Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22(2):155-7.
57. Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627-32.
58. Adán A, Llorenç V, Mesquida M, Pelegrín L. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(9):2249-50.
59. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot J-F, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19(5):382-3.
60. Smith TJ, Tsai CC, Shih M-J, Tsui S, Chen B, Han R, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):983-8.
61. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281-7.
62. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181(8):5768-74.
63. Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology. 2006;147(4):1941-9.
64. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89(10):5076-80.
65. Ezra DG, Krell J, Rose GE, Bailly M, Stebbing J, Castellano L. Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. J Clin Pathol. 2012;65(7):608-13.
66. Salvi M. Immunotherapy for Graves' ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):409-14.
67. Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes. Cancer Res. 2012;72:2695-700.
68. Bennani YL. Drug discovery in the next decade: Innovation needed ASAP. Drug Discov Today. 2011;16:779-92.
69. McNally S, O'Brien CJ. Drug discovery in glaucoma and the role of animal models. In: Drug Discovery Today: Disease Models. 2014.
70. Zeiss CJ. Translational models of ocular disease. Vet Ophthalmol. 2013;16:15-33.
71. Bouhenni RA, Dunmire J, Sewell A, Edward DP. Animal models of glaucoma. J Biomed Biotechnol. 2012;2012:692609.
72. Zeiss CJ. Animals as models of age-related macular degeneration: an imperfect measure of the truth. Vet Pathol. 2010;47(3):396-413.
73. Caspi RR. Understanding autoimmunity in the eye: from animal models to novel therapies. Discov Med. 2014;17(93):155-62.
74. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24(6):802-35.
75. Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. Endocrinology. 2005;146(2):835-44.
76. Many MC, Costagliola S, Detrait M, Denef F, Vassart G, Ludgate MC. Development of an animal model of autoimmune thyroid eye disease. J Immunol. 1999;162(8):4966-74.
77. Costagliola S, Many MC, Stalmans-Falys M, Tonacchera M, Vassart G, Ludgate M. Recombinant thyrotropin receptor and the induction of autoimmune thyroid disease in BALB/c mice: a new animal model. Endocrinology. 1994;135(5):2150-9.
78. Costagliola S, Alcalde L, Tonacchera M, Ruf J, Vassart G, Ludgate M. Induction of thyrotropin receptor (TSH-R) autoantibodies and thyroiditis in mice immunised with the recombinant TSH-R. Biochem Biophys Res Commun. 1994;199(2):1027-34.
79. Costagliola S, Many MC, Stalmans-Falys M, Vassart G, Ludgate M. Transfer of thyroiditis, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive BALB/c and NOD mice. Endocrinology. 1996;137(11):4637-43.
80. Moshkelgosha S, So P-W, Deasy N, Diaz-Cano S, Banga JP. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology. 2013;154(9):3008-15.
81. Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today. 2012;17:253-60.
82. Das Thakur M, Pryer NK, Singh M. Mouse tumour models to guide drug development and identify resistance mechanisms. J Pathol. 2014;232:103-11.
83. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-5.
84. Thrimawithana TR, Young S, Bunt CR, Green CR, Puglisi G, Alany RG. Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities. Drug Deliv Lett. 2011;1:40-4.
85. Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441-63.
86. Ye T, Yuan K, Zhang W, Song S, Chen F, Yang X, et al. Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci. 2013;8(4):207-17.
87. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27(4):530-43.
88. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875-912.
89. On Demand Therapeutics. www.ondemandtx.com. Accessed Sept 2015
90. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-5.
91. Neurotech. www.neurotechusa.com. Accessed Sept 2015
92. Weiner AL, Gilger BC. Advancements in ocular drug delivery. Vet Ophthalmol. 2010;13(6):395-406.
93. Bengani LC, Hsu K-H, Gause S, Chauhan A. Contact lenses as a platform for ocular drug delivery. Expert Opin Drug Deliv. 2013;10(11):1483-96.
94. Eye gate pharma. www.eyegatepharma.com. Accessed Sept 2015.
95. Halhal M, Renard G, Courtois Y, BenEzra D, Behar-Cohen F. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004;78(3):751-7.
96. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov. 2011;10:328-9.
97. Deyati A, Younesi E, Hofmann-Apitius M, Novac N. Challenges and opportunities for oncology biomarker discovery. Drug Discov Today. 2013;18:614-24.
98. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500.
99. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28:4769-77.
100. Kim G, McKee AE, Ning Y-M, Hazarika M, Theoret M, Johnson JR, et al. FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. Clin Cancer Res. 2014;20(19):4994-5000.
101. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
102. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov. 2009;8(1):15-6.
103. Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of Adenosine Agonists on Intraocular Pressure and Aqueous Humor Dynamics in Cynomolgus Monkeys. Exp Eye Res. 1997;64(6):979-89.
104. Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302-7.
105. Lewis RA, Levy B, Ramirez N, C Kopczynski C, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2015, [Epub ahead of print]